Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage

Sen, Jon, Belli, Antonio, Albon, Helen, Morgan, Laleh, Petzold, Axel and Kitchen, Neil (2003) Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage. Lancet Neurology, 2, (10), 614-620. (doi:10.1016/S1474-4422(03)00531-3).


Full text not available from this repository.


Cerebral vasospasm is a recognised but poorly understood complication for many patients who have aneurysmal subarachnoid haemorrhage and can lead to delayed ischaemic neurological deficit (stroke). Morbidity and mortality rates for vasospasm are high despite improvements in management. Since the middle of the 1970s, much has been written about the treatment of cerebral vasospasm. Hypervolaemia, hypertension, and haemodilution (triple-H) therapy in an intensive-care setting has been shown in some studies to improve outcome and is an accepted means of treatment, although a randomised controlled trial has never been undertaken. In this review, the rationale for this approach will be discussed, alongside new thoughts and future prospects for the management of this complex disorder.

Item Type: Article
Digital Object Identifier (DOI): doi:10.1016/S1474-4422(03)00531-3
ISSNs: 1474-4422 (print)
Related URLs:
Subjects: R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
R Medicine > RM Therapeutics. Pharmacology
Divisions : University Structure - Pre August 2011 > School of Medicine > Clinical Neurosciences
ePrint ID: 27710
Accepted Date and Publication Date:
October 2003Published
Date Deposited: 25 Apr 2006
Last Modified: 31 Mar 2016 11:52

Actions (login required)

View Item View Item